DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia

Leukemia

Volumn 13, Issue 4, 1999, Pages 629-633

  Hall, P D ^a   Willingham, M C ^b   Kreitman, R J ^c   Frankel, A E ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

huGM CSF diphtheria toxin fusion protein; SCID mouse leukemia model

Indexed keywords

CYTARABINE; DIPHTHERIA TOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; DT(388) GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; DT(388) GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTOXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; ANIMAL; CANCER TRANSPLANTATION; CELL STRAIN HL 60; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; MOUSE MUTANT; PATHOLOGY; SALVAGE THERAPY; TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; SALVAGE THERAPY;

EID: 0032588869     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401357     Document Type: Article

References (17)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
2. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E for the Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
3. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217-223.
4. Kelleher CA, Wong GG, Clark SC, Schendal PF, Minder M, McCoulloch EA. Binding of iodinated recombinant human GM-CSF to the blast cells of acute myeloblastic leukemia. Leukemia 1988; 2: 211-215.
5. Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood 1997; 90: 3654-3661.
6. Kreitman RJ, Pastan I. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 1997; 90: 252-259.
7. Bendel AE, Shao Y, Davies SM, Warman B, Yang CH, Waddick KG, Uckun FM, Perentesis JP. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Leuk Lymphoma 1997; 25: 257-270.
8. Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood 1998; 92: 589-595.
9. Terpstra W, Rozenmuller H, Breems DA, Rombouts EJC, Prins A, Fitzgerald DJP, Kreitman RJ, Wielenga JJ, Ploemacher RE, Lowenberg B, Hagenbeek A, Martens ACM. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hematopoietic stem cells. Blood 1997; 90: 3735-3742.
10. 388) linked to human granulocyte-macrophage colony-stimulating factor (CM-CSF), in C57BL/6 mice. Toxicol Appl Pharmacol 1998; 150: 91-97.
11. Dalton WT, Ahearn MJ, McCrdie KB, Freireich EJ, Stass SA, Trujilo JM. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 1988; 71: 242-247.
12. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 1992; 7: 827-836.
13. Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, Freedman MH, Phillips RA, Dick JE. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science 1989; 246: 1597-1600.
14. Perentesis JP, Gunther R, Waurzyniak B, Yanishevski Y, Myers DE, Ek O, Messinger Y, Shao Y, Chelstrom LM, Schneider E, Evans WE, Uckun FM. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte-macrophage colony-stimulating factor receptor. Clin Cancer Res 1997; 3: 2217-2227.
15. Sawyers CL, Gishizky ML, Quan S, Golde DW, Wirte ON. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 1992; 79: 2089-2098.
16. Goldmacher VS. Isolation and analysis of somatic cell mutants resistant to toxin conjugates. Cancer Treat Res 1988; 37: 417-430.
17. Moehring JM, Moehring TJ, Danley DE. Postranslational modification of elongation factor 2 in diphtheria-toxin-resistant mutants of CHO-K1 cells. Proc Natl Acad Sci USA 1980; 77: 1010-1014.